Sage Therapeutics SAGE Stock
Sage Therapeutics Price Chart
Sage Therapeutics SAGE Financial and Trading Overview
Sage Therapeutics stock price | 6.66 USD |
Previous Close | 58.04 USD |
Open | 57.94 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 800 |
Day's Range | 55.98 - 58.03 USD |
52 Week Range | 31.42 - 59.99 USD |
Volume | 750.09K USD |
Avg. Volume | 513.53K USD |
Market Cap | 3.35B USD |
Beta (5Y Monthly) | 1.155281 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.59 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 61.59 USD |
SAGE Valuation Measures
Enterprise Value | 2.35B USD |
Trailing P/E | N/A |
Forward P/E | -6.500579 |
PEG Ratio (5 yr expected) | -0.18 |
Price/Sales (ttm) | 356.7412 |
Price/Book (mrq) | 2.9587045 |
Enterprise Value/Revenue | 249.995 |
Enterprise Value/EBITDA | -4.064 |
Trading Information
Sage Therapeutics Stock Price History
Beta (5Y Monthly) | 1.155281 |
52-Week Change | 65.68% |
S&P500 52-Week Change | 20.43% |
52 Week High | 59.99 USD |
52 Week Low | 31.42 USD |
50-Day Moving Average | 49.91 USD |
200-Day Moving Average | 42.83 USD |
SAGE Share Statistics
Avg. Volume (3 month) | 513.53K USD |
Avg. Daily Volume (10-Days) | 645.93K USD |
Shares Outstanding | 59.76M |
Float | 52.26M |
Short Ratio | 10.35 |
% Held by Insiders | 12.49% |
% Held by Institutions | 88.82% |
Shares Short | 5.41M |
Short % of Float | 11.83% |
Short % of Shares Outstanding | 9.05% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -6163.65% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -24.74% |
Return on Equity (ttm) | -40.52% |
Income Statement
Revenue (ttm) | 9.4M USD |
Revenue Per Share (ttm) | 0.16 USD |
Quarterly Revenue Growth (yoy) | 108.20% |
Gross Profit (ttm) | -319290000 USD |
EBITDA | -578089984 USD |
Net Income Avi to Common (ttm) | -557556992 USD |
Diluted EPS (ttm) | -9.43 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.13B USD |
Total Cash Per Share (mrq) | 18.9 USD |
Total Debt (mrq) | 10.45M USD |
Total Debt/Equity (mrq) | 0.92 USD |
Current Ratio (mrq) | 14.21 |
Book Value Per Share (mrq) | 18.961 |
Cash Flow Statement
Operating Cash Flow (ttm) | -505918016 USD |
Levered Free Cash Flow (ttm) | -308794496 USD |
Profile of Sage Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | 215 First Street |
ZIP | 02142 |
Phone | 617 299 8380 |
Website | https://www.sagerx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 689 |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Sage Therapeutics Stock
What is a current SAGE stock price?
Sage Therapeutics SAGE stock price today per share is 6.66 USD.
How to purchase Sage Therapeutics stock?
You can buy SAGE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sage Therapeutics?
The stock symbol or ticker of Sage Therapeutics is SAGE.
Which industry does the Sage Therapeutics company belong to?
The Sage Therapeutics industry is Biotechnology.
How many shares does Sage Therapeutics have in circulation?
The max supply of Sage Therapeutics shares is 61.48M.
What is Sage Therapeutics Price to Earnings Ratio (PE Ratio)?
Sage Therapeutics PE Ratio is now.
What was Sage Therapeutics earnings per share over the trailing 12 months (TTM)?
Sage Therapeutics EPS is -6.59 USD over the trailing 12 months.
Which sector does the Sage Therapeutics company belong to?
The Sage Therapeutics sector is Healthcare.
Sage Therapeutics SAGE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Biotechnology Total Retu XNBI | 4172.84 USD — |
-1.22
|
— — | 4004.28 USD — | 4291.75 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 1913.4 USD — |
-1.32
|
— — | 1835.13 USD — | 2001.25 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2497.76 USD — |
-0.11
|
— — | 2369.22 USD — | 2594.76 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19098.57 USD — |
+0.1
|
— — | 18095.83 USD — | 19941.93 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1638.71 USD — |
-0.55
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}